Wearable Cardioverter Defibrillators Market Size & Share by Indication (Myocardial Infarction, Congenital Heart Disease, Ventricular Arrhythmias, Peripartum Cardiomyopathy, Tetralogy Of Fallot, Wolff-Parkinson-White Syndrome); Demography (Pediatric, Adults, Geriatric); End-user (Home Care Settings, Hospitals, Cardiology Clinics, Ambulatory Surgical Center) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 874
  • Published Date: Nov 17, 2023
  • Report Format: PDF, PPT

Companies Dominating the Wearable Cardioverter Defibrillators Landscape

top-features-companies
    • ZOLL Medical Corporation
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Element Science Inc.
    • Medtronic plc
    •  Kestra Medical Technologies, Inc.
    •  Abbott
    •  Boston Scientific Corporation
    •  LivaNova plc
    •  Koninklijke Philips N.V.
    •  Nihon Kohden Corporation
    •  General Electric Company.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Medtronic plc announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) for Aurora EV-ICD MRI SureScan (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV MRI SureScan to offer the advantages of conventional, transvenous ICDs in terms of saving lives by providing anti-tachycardia pacing (ATP), backup (pause-prevention) pacing therapy, and life-saving defibrillation.
  • Abbott received approval from the U.S. Food and Drug Administration (FDA) for Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices with Bluetooth technology and a new patient smartphone app for better remote monitoring for patients with cardiac rhythm abnormalities.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 874
  • Published Date: Nov 17, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising incidence of heart attacks across the globe and the growing technological advancement in cardiology are the major factors driving the growth of the market.

The market size of Wearable Cardioverter Defibrillators is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024 – 2036.

The major players in the market are ZOLL Medical Corporation, Element Science Inc., Medtronic plc, Kestra Medical Technologies, Inc., Abbott, Boston Scientific Corporation, LivaNova plc, Koninklijke Philips N.V., Nihon Kohden Corporation and General Electric Company., and others.

The peripartum cardiomyopathy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying